Head and neck cancer: high-end technology is no guarantee of high-quality care - Authors' reply. Read more about Head and neck cancer: high-end technology is no guarantee of high-quality care - Authors' reply.
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Read more about The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
Oncogenic NTRK fusion in congenital spinal cord glioblastoma: sequencing directs treatment. Read more about Oncogenic NTRK fusion in congenital spinal cord glioblastoma: sequencing directs treatment.
Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply. Read more about Pembrolizumab plus chemotherapy in triple-negative breast cancer - Authors' reply.
The psychological impact of deprivation in regions affected by conflict: a multilevel analysis of a cross-sectional survey in the occupied Palestinian territory. Read more about The psychological impact of deprivation in regions affected by conflict: a multilevel analysis of a cross-sectional survey in the occupied Palestinian territory.
Food insecurity in the context of conflict: analysis of survey data in the occupied Palestinian territory. Read more about Food insecurity in the context of conflict: analysis of survey data in the occupied Palestinian territory.
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Read more about KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Read more about Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
